- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02241200
A Study in Healthy Volunteers to Compare the Profiles of DA-3880 and EU Sourced ARANESP® (Amgen)
June 13, 2021 updated by: Dong-A ST Co., Ltd.
A Randomized, 2 Part, 4-treatment, 2-way Cross-over Study in Healthy Volunteers to Compare the Pharmacokinetic and Pharmacodynamic Profiles of 1ug/kg of DA-3880 and EU Sourced ARANESP® (Amgen) After Single Intravenous or Subcutaneous Administration
The main purpose of the study is to determine whether the test product and the reference product are bioequivalent based on the pharmacokinetics after administration of ug/kg as a single intravenous dose and as a single subcutaneous dose of each of the formulations.
The study is consisted of randomization, 2 parts, 4 treatments, 2 way cross over.
Study Overview
Study Type
Interventional
Enrollment (Actual)
64
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Zuidlaren, Netherlands, 9471
- PRA
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Gender : male or female
- Age : 18 - 65 years, inclusive
- Body Mass Index (BMI) : 18.0 - 30.0 kg/m2, inclusive
- Weight : 55 - 105 kg, inclusive
- Female subjects of childbearing potential must be non-pregnant and non-lactating, and have a negative pregnancy test at screening and (each) admission to the clinical research center
- Females of child-bearing potential, with a fertile male sexual partner, should be willing to use adequate contraception from screening until 90 days after the follow-up visit. Adequate contraception is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom.
- Males should be willing to use adequate contraception and not donate sperm from first admission to the clinical research center until 90 days after the follow-up visit. Adequate contraception for the male subject and his female partner, is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom.
- All non-regular medication (including over the counter medication, health supplements, and herbal remedies such as St. John's Wort extract) must have been stopped at least 14 days prior to (the first) admission to the clinical research center. An exception is made for paracetamol (acetaminophen), which is allowed up to admission to the clinical research center. Other exceptions are multivitamins and vitamin C, which are allowed up to 7 days before admission to the clinical research center.
- All regular non-topical medication must have been stopped at least 30 days prior to (the first) admission the clinical research center. An exception is made for hormonal contraceptives, which may be used throughout the study.
- Ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, cola, chocolate, "powerdrinks"), grapefruit (juice) and tobacco products from 48 h prior to each admission to in the clinical research center
- Medical history without major pathology as judged by the PI
- Normal resting supine blood pressure and pulse showing no clinically relevant deviations as judged by the PI.
- Computerized (12-lead) electrocardiogram (ECG) recording without signs of clinically relevant pathology or showing no clinically relevant deviations as judged by the PI.
- All values for clinical laboratory tests of blood and urine within the normal range or showing no clinically relevant deviations as judged by the PI. Hb, Hct, RBC count and thrombocytes should not exceed the upper limit of normal. Minor deviations can be accepted at the discretion of the PI
- Willing and able to sign the ICF
Exclusion Criteria:
- Evidence of clinically relevant pathology
- Mental handicap
- History of relevant drug and/or food allergies, and/or latex allergy
- Smoking more than 10 cigarettes, 2 cigars or 2 pipes daily; the use of tobacco products in the 48 hours (2 days) prior to each admission to the clinical research center is not allowed.
- History of alcohol or drug abuse or drug addiction (including soft drugs like cannabis products)
- Positive drug screen (opiates, methadone, cocaine, amphetamines [including ecstasy], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants and alcohol)
- Average intake of more than 24 units of alcohol per week: one unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)
- Consumption of any foods containing poppy seeds within 48 hours (2 days) prior to each admission to the clinical research center as this could cause a false positive drug screen result
- Positive screen on hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies or anti-HIV 1 and 2 antibodies
- Participation in a drug study within 60 days prior to the screening visit in the current study. Participation in more than 3 other drug studies (for men) and more than 2 other drug studies (for women) in the 10 months prior to the first drug administration in the current study
- Donation or loss of more than 100 mL of blood within 60 days prior to the first drug administration. Donation or loss of more than 1.5 liters of blood (for men) / more than 1.0 liters of blood (for women) in the 10 months prior to the first drug administration in the current study.
- Strenuous exercise within 96 hours (4 days) prior to each admission to the clinical research center.
- Significant and/or acute illness within 5 days prior to the first drug administration that may impact safety assessments, in the opinion of the PI
- Vaccination within 30 days prior to entry into the clinical research center or planning a vaccination before the follow-up visit
- History of a significant respiratory disorder (such as asthma) or significant immune disorder
- Significant infection within 30 days prior to entry into the clinical research center
- History of epilepsy; a single febrile convulsion at an age < 6 years is acceptable
- History of hemoglobinopathy or abnormal Hb in first-degree relatives
- A previous administration of any erythropoiesis-stimulating agent including EPO or darbepoetin, if known
- Previous immunoglobulin or iron supplementation within 3 months prior to the screening visit
- History of hypersensitivity reactions for any EPO, darbepoetin, iron supplements, or excipient of the investigational product
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IV Administration
The iv solutions containing DA-3880 and Aranesp will be indistinguishable in appearance.
|
|
Experimental: SC Administration
The sc solutions containing DA-3880 and Aranesp will be indistinguishable in appearance.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics of DA-3880 and Aranesp via IV Administration
Time Frame: 6 weeks
|
AUC0-t, Cmax, Tmax, t½, AUC0-inf, %AUC of DA-3880 and EU sourced Aranesp® (Amgen) after administration of 1 μg/kg as a single iv dose will be assessed.
|
6 weeks
|
Pharmacokinetics of DA-3880 and Aranesp via SC Administration
Time Frame: 6 weeks
|
AUC0-t, Cmax, Tmax, t½, AUC0-inf, %AUC of DA-3880 and EU sourced Aranesp® (Amgen) after administration of 1 μg/kg as a single sc dose will be assessed
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacodynamic Variables of DA-3880 and Aranesp
Time Frame: 6 weeks
|
AUEC0-t, Emax, Tmax of DA-3880 and EU sourced Aranesp® after administration of 1 μg/kg as a single iv dose and as a single sc dose will be assessed.
|
6 weeks
|
Safety and Tolerability Parameters of DA-3880 and Aranesp
Time Frame: 6 weeks
|
Adverse events, vital signs, 12-lead ECG, clinical laboratory tests, physical examination, immunogenicity (anti-drug antibodies), local tolerability of DA-3880 and EU sourced Aranesp® after administration of 1 μg/kg as a single iv dose and as a single sc dose will be assessed.
|
6 weeks
|
Pharmacodynamic and Pharmacodynamic Variables of IV and SC Administration
Time Frame: 6 weeks
|
AUC0-t, Cmax, Tmax, t½, AUC0-inf, %AUC, AUEC0-t, Emax, Tmax of DA-3880 (1 μg/kg) and EU sourced Aranesp® (1 μg/kg) after iv administration with those after sc administration will be assessed.
|
6 weeks
|
Safety and Tolerability Parameters of SC and IV Administration
Time Frame: 6 weeks
|
Adverse events, vital signs, 12-lead ECG, clinical laboratory tests, physical examination, immunogenicity (anti-drug antibodies), local tolerability of DA-3880 (1 μg/kg) and EU sourced Aranesp® (1 μg/kg) after iv administration with those after sc administration will be compared and assessed.
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 18, 2014
Primary Completion (Actual)
November 29, 2014
Study Completion (Actual)
November 29, 2014
Study Registration Dates
First Submitted
August 29, 2014
First Submitted That Met QC Criteria
September 12, 2014
First Posted (Estimate)
September 16, 2014
Study Record Updates
Last Update Posted (Actual)
June 15, 2021
Last Update Submitted That Met QC Criteria
June 13, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DA3880_ANE_I
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Symptomatic Anemia
-
Hospira, now a wholly owned subsidiary of PfizerCompletedSolid Tumors | Lymphomas | Chemotherapy-induced Symptomatic Anemia | Malignant Hemopathies | MyelomasFrance
-
University Hospital, AkershusTerminatedSymptomatic Haemorrhoidal DiseaseNorway
-
Abramson Cancer Center of the University of PennsylvaniaCompleted
-
Alcon ResearchCompletedSymptomatic Contact Lens WearersUnited States
-
Xijing HospitalUnknownSymptomatic Cervical Disc Disease
-
Pierre FontanaMinistry of Health, France; University Hospital, Montpellier; Swiss National... and other collaboratorsCompleted
-
Medtronic Surgical TechnologiesWithdrawnMacromastia (Symptomatic)United States
-
Cook Research IncorporatedCompletedSymptomatic Venous Outflow Obstruction in the Iliofemoral VeinUnited States, Taiwan
-
Sun Pharmaceutical Industries LimitedCompletedActive, Symptomatic BlepharitisUnited States
-
Dr. Ivan KristoCompletedSymptomatic Heterotopic Gastric Mucosa
Clinical Trials on Aranesp
-
University of LiegeKU Leuven; Amgen; Vrije Universiteit BrusselCompletedHematological MalignanciesBelgium
-
AmgenTerminated
-
AmgenTerminatedCancer | Anemia | Non-Small Cell Lung Cancer | Lung CancerUnited States, Belgium, Italy, Poland, Switzerland, Canada, Germany, Russian Federation, China, Taiwan, United Kingdom, Hong Kong, Austria, Brazil, Israel, South Africa, Czechia, Greece, Spain, Netherlands, Bulgaria, Romania, Ireland, Puerto Rico and more
-
Sir Charles Gairdner HospitalCompletedAnemia | Kidney Failure, ChronicAustralia
-
AmgenCompletedAnemia in Chronic Kidney Disease Patients Not on DialysisUnited States, Puerto Rico
-
AmgenCompletedMDSGermany, Italy, Belgium, Czechia, Switzerland, France, Austria, Greece, Spain
-
University of Maryland, BaltimoreAmgenCompletedAnemia | Chronic Kidney Disease | CardiomyopathyUnited States
-
BiocadCompletedHealthyRussian Federation